The U.S. Food and Drug Administration has already approved Johnson & Johnson’s COVID-19 vaccine that works with just one dose for emergency use in February
Global healthcare major Johnson & Johnson is in discussions with the Indian government to begin a clinical trial of its single-dose COVID-19 vaccine in the country, the company said on Friday.
The U.S. Food and Drug Administration has already approved Johnson & Johnson’s COVID-19 vaccine that works with just one dose for emergency use in February.
“We are in discussions with the Government of India with the objective of starting a bridging clinical study of our Janssen COVID-19 vaccine candidate in India, subject to local regulatory approvals,” Johnson & Johnson India spokesperson said in an email reply.
Johnson & Johnson’s vaccine can be stored at refrigerator temperatures.
“At Johnson & Johnson, we remain fully focused on bringing a safe and effective COVID-19 vaccine to people around the world, if authorised for use by local health authorities”, the spokesperson said.
India is currently using two vaccines for COVID-19 — one developed by Oxford University and AstraZeneca and the other developed by Bharat Biotech in collaboration with the Indian Council of Medical Research – National Institute of Virology. Both the vaccines are being manufactured within the country by domestic firms.
India registered a record single-day spike of 1,31,968 new COVID-19 cases on Friday, pushing its infection tally to 1,30,60,542, while the death toll increased to 1,67,642 with 780 more fatalities in a day, the highest since October 18, the Union Health Ministry data showed.
